Bae S, et al. - Authors ascertained the use of oral cyclophosphamide (PO CYC) in a single center longitudinal cohort of patients with idiopathic inflammatory myopathies (IIM). Following CYC use, disease activity measures significantly improved and concomitant daily prednisone dose decreased. During CYC therapy, infection were the most common adverse events. This was the first cohort study of PO CYC use in IIM patients with severe, treatment refractory disease.